Diversities in the Gut Microbial Patterns in Patients with Atherosclerotic Cardiovascular Diseases and Certain Heart Failure Phenotypes
-
Published:2022-10-31
Issue:11
Volume:10
Page:2762
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Drapkina Oxana M.ORCID, Ashniev German A., Zlobovskaya Olga A.ORCID, Yafarova Adel A., Dementeva Elena V.ORCID, Kaburova Anastasia N.ORCID, Meshkov Ivan O., Sheptulina Anna F.ORCID, Kiselev Anton R.ORCID, Kontsevaya Anna V., Zhamalov Linar M.ORCID, Koretskiy Sergey N., Pokrovskaya Mariya S., Akinshina Alexandra I., Zagaynova Anjelica V., Lukashina Mariia V., Kirillov Andrey V., Abramov Ivan A.ORCID, Tolkacheva Larisa R., Bikaeva Irina O., Glazunova Evgeniya V., Shipulin German A., Bobrova Maria M., Makarov Valentin V., Keskinov Anton A., Yudin Vladimir S.ORCID, Yudin Sergey M.
Abstract
To continue progress in the treatment of cardiovascular disease, there is a need to improve the overall understanding of the processes that contribute to the pathogenesis of cardiovascular disease (CVD). Exploring the role of gut microbiota in various heart diseases is a topic of great interest since it is not so easy to find such reliable connections despite the fact that microbiota undoubtedly affect all body systems. The present study was conducted to investigate the composition of gut microbiota in patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure syndromes with reduced ejection fraction (HFrEF) and HF with preserved EF (HFpEF), and to compare these results with the microbiota of individuals without those diseases (control group). Fecal microbiota were evaluated by three methods: living organisms were determined using bacterial cultures, total DNA taxonomic composition was estimated by next generation sequencing (NGS) of 16S rRNA gene (V3–V4) and quantitative assessment of several taxa was performed using qPCR (quantitative polymerase chain reaction). Regarding the bacterial culture method, all disease groups demonstrated a decrease in abundance of Enterococcus faecium and Enterococcus faecalis in comparison to the control group. The HFrEF group was characterized by an increased abundance of Streptococcus sanguinus and Streptococcus parasanguinis. NGS analysis was conducted at the family level. No significant differences between patient’s groups were observed in alpha-diversity indices (Shannon, Faith, Pielou, Chao1, Simpson, and Strong) with the exception of the Faith index for the HFrEF and control groups. Erysipelotrichaceae were significantly increased in all three groups; Streptococcaceae and Lactobacillaceae were significantly increased in ASCVD and HFrEF groups. These observations were indirectly confirmed with the culture method: two species of Streptococcus were significantly increased in the HFrEF group and Lactobacillus plantarum was significantly increased in the ASCVD group. The latter observation was also confirmed with qPCR of Lactobacillus sp. Acidaminococcaceae and Odoribacteraceae were significantly decreased in the ASCVD and HFrEF groups. Participants from the HFpEF group showed the least difference compared to the control group in all three study methods. The patterns found expand the knowledge base on possible correlations of gut microbiota with cardiovascular diseases. The similarities and differences in conclusions obtained by the three methods of this study demonstrate the need for a comprehensive approach to the analysis of microbiota.
Funder
Federal Medical Biological Agency Centre for Strategic Planning and Management of Biomedical Health Risks of Federal Medical Biological Agency of Russia
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference47 articles.
1. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015;Kassebaum;Lancet,2016 2. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015;Wang;Lancet,2016 3. GBD 2019 Diseases and Injuries Collaborators.Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019;Vos;Lancet,2020 4. Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis;Khatana;Oxid. Med. Cell. Longev.,2020 5. Mathers, C.D., and Loncar, D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLOS Med., 2006. 3.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|